Karijn P M Suijkerbuijk
Overview
Explore the profile of Karijn P M Suijkerbuijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
de Groot S, Blommestein H, Leeneman B, Uyl-de Groot C, Haanen J, Wouters M, et al.
Med Decis Making
. 2025 Feb;
:272989X251319338.
PMID: 39985400
Background: A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives: To develop a decision model for advanced melanoma...
2.
Schuiveling M, Ter Maat L, Van Duin I, Verheijden R, Troenokarso M, Moeskops P, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39980388
Introduction: The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside...
3.
Schuiveling M, Liu H, Eek D, Breimer G, Suijkerbuijk K, Blokx W, et al.
Gigascience
. 2025 Feb;
14.
PMID: 39970004
Background: Melanoma is an aggressive form of skin cancer in which tumor-infiltrating lymphocytes (TILs) are a biomarker for recurrence and treatment response. Manual TIL assessment is prone to interobserver variability,...
4.
Blommestein H, de Groot S, Leeneman B, Uyl-de Groot C, Haanen J, Wouters M, et al.
Eur J Cancer
. 2025 Feb;
218:115071.
PMID: 39914026
Background: This study aims to evaluate the cost-effectiveness of treatment sequences for patients with advanced melanoma with a BRAF mutation in the Netherlands from a societal perspective. Methods: A semi-Markov...
5.
Verheijden R, van Eijs M, Paganelli F, Viveen M, Rogers M, Top J, et al.
Eur J Cancer
. 2025 Jan;
216:115221.
PMID: 39793444
Background: Multiple studies have suggested that gut microbiome may influence immune checkpoint inhibitor (ICI) efficacy, but its association with immune-related adverse events (irAEs) is less well studied. In this prospective...
6.
Ter Maat L, De Mooij R, Van Duin I, Verhoeff J, Elias S, Leiner T, et al.
Sci Rep
. 2024 Dec;
14(1):31668.
PMID: 39738216
Immune checkpoint inhibitor (ICI) treatment has proven successful for advanced melanoma, but is associated with potentially severe toxicity and high costs. Accurate biomarkers for response are lacking. The present work...
7.
Reijers I, Menzies A, Lopez-Yurda M, Versluis J, Rozeman E, Saw R, et al.
Eur J Cancer
. 2024 Nov;
214():115141.
PMID: 39602990
Background: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, response-directed treatment strategies. Methods:...
8.
Verheijden R, de Groot J, Fabriek B, Hew M, May A, Suijkerbuijk K
J Clin Oncol
. 2024 Nov;
43(5):616-619.
PMID: 39546742
No abstract available.
9.
van Gogh M, Louwers J, Celli A, Grave S, Viveen M, Bosch S, et al.
Microbiome
. 2024 Oct;
12(1):211.
PMID: 39434178
Background: The intestinal microbiota plays a significant role in maintaining systemic and intestinal homeostasis, but can also influence diseases such as inflammatory bowel disease (IBD) and cancer. Certain bacterial species...
10.
Koldenhof J, Akpobome B, Zweers D, Klaasse S, Teunissen S, Witteveen P, et al.
J Patient Rep Outcomes
. 2024 Oct;
8(1):120.
PMID: 39422800
Introduction: The Utrecht Symptom Diary (USD) is a validated Dutch patient-reported outcome measurement (PROM) tool - based on the Edmonton Symptom Assessment System - to assess and monitor symptoms in...